PLOD2 and nonpapillary renal cell carcinoma: Results from the TCGA-KIRC cohort also revealed that ccRCC patients with high PLOD2 expression had higher disease-specific survival rates (DSS) and progression-free survival rates (DFS) than those with low PLOD2 expression (Fig. 3E, F).